TO CREATING THE AWARENESS IN THE PATIENT USING THE PMOS MEDICATION IN THE REGION OF DEHRADUN

AbstractPolycystic Ovary Syndrome (PCOS), also referred to in some literature as PolyendocrineMetabolic Ovarian Syndrome (PMOS), is one of the most common endocrine disordersaffecting women of reproductive age and is associated with reproductive, metabolic, andpsychological complications. Pharmacological management, including metformin, combinedoral contraceptives, antiandrogens, inositol, and glucagon-like peptide-1 (GLP-1) receptoragonists, plays a vital role in symptom control and prevention of long-term complications.Despite the availability of effective therapeutic options, inadequate patient awarenessregarding medication use, mechanism of action, expected therapeutic outcomes, adverse drugreactions, and the importance of medication adherence remains a major barrier to successfuldisease management. This review summarizes the current evidence on pharmacologicaltherapies used in PCOS/PMOS and highlights the importance of medication awareness inimproving clinical outcomes. Recent literature demonstrates that pharmacist-led educationalinterventions, structured counselling, and patient-centered communication significantlyenhance medication knowledge, adherence, treatment satisfaction, and overall quality of life.Furthermore, patient education contributes to better recognition and management of adverseeffects, promotes shared decision-making, and reduces unnecessary discontinuation oftherapy. The review also discusses the expanding role of clinical pharmacists inmultidisciplinary PCOS care, emphasizing their contribution to medication therapymanagement and health promotion. Recent advances in digital health technologies,telepharmacy, and personalized educational strategies are also explored as promisingapproaches to strengthen patient engagement and long-term disease management. Overall,improving medication awareness should be considered an essential component ofcomprehensive PCOS management. Integrating evidence-based educational programs withroutine pharmacological care has the potential to optimize therapeutic outcomes, enhancemedication adherence, minimize complications, and improve the overall health and quality oflife of women living with PCOS/PMOS.